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Primary Membranous 
Nephropathy as a Model of 
Autoimmune Disease
Patrick Hamilton, Durga Kanigicherla and Paul Brenchley
Abstract
Membranous nephropathy is the most common cause of adult nephrotic syn-
drome worldwide with a significant health care burden. There has been a leap in 
our understanding of the disease mechanism over the last decade with a remarkably 
strong genetic component to the development of the disease and its strong associa-
tion with high affinity antibody—in the form of anti-PLA2R autoantibody in the 
majority of cases, with a smaller proportion associated with anti-THSD7A auto-
antibody. New evidence is now providing confirmation of specific elements in the 
development of the disease pathogenesis, such as involvement of loss of peripheral 
tolerance. There is a striking correlation between disease activity and anti-PLA2R 
antibody levels, along with response to treatment; evidence points strongly to these 
antibodies being pathogenic. The development of membranous nephropathy there-
fore follows the well appreciated multi-hit step-wise path to autoimmune clinical 
disease. Given its strong genetic basis and putative pathogenic antibody the disease 
provides an invaluable model for understanding of autoimmunity. This chapter 
focuses on the most up to date knowledge of autoimmune membranous nephropa-
thy and provides a paradigm for understanding the underlying disease mechanisms 
in autoimmunity.
Keywords: autoimmune disease, membranous nephropathy, nephrotic syndrome, 
anti-PLA2R
1. Introduction
Autoimmune disease is a term that covers a range of conditions in which the 
immune system recognises the body as a foreign pathogen, and encompasses 
over 80 conditions affecting almost every organ [1]. Individually, many of these 
conditions are rare but taken together they represent a significant mortality and 
morbidity affecting approximately 9% of the population worldwide with the 
prevalence rising [1, 2]. Given that the majority of conditions have no cure and 
potentially require lifelong treatment, and that most patients are diagnosed during 
young adulthood or in middle age, the cost to healthcare systems is particularly 
significant.
Despite the variation of organs affected and clinical presentation, many of the 
conditions that appear distinct will share a common theme of disease pathogen-
esis. Underscoring many of the conditions is a genetic susceptibility that taken in 
concert with an environmental trigger sets off an immune cascade resulting in the 
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end organ damage and clinical signs and symptoms that bring the patient to the 
attention of their healthcare provider, the so-called multi-hit hypothesis. As science 
progresses and we gain greater insight into these disease processes, it is becoming 
more apparent that there are similarities in many of the conditions. At present, 
most management strategies attempt to globally restrict the immune system, a 
strategy that has been shown to help control the disease but comes with a significant 
side effect profile. Despite the accelerating knowledge we are gaining of the under-
lying pathogenesis, there remains a lack of directed novel therapies for patients at 
present, although in many conditions there are signs that this is changing.
Membranous nephropathy represents a particularly interesting basis to under-
stand this process given its clear pathological classification, strong genetic contribu-
tion, putative pathogenic antibody and evidence for the loss of tolerance that is now 
emerging. In this chapter, we review the current understanding of autoimmune 
membranous nephropathy and use it as a basis for the understanding of autoim-
mune disease in general.
2. Background
Membranous nephropathy (MN) is the most common cause of nephrotic 
syndrome in adults worldwide but despite this remains a rare disease. Incidence is 
estimated at 1.2 per 100,000 in European cohorts with a peak incidence in the fifth 
and sixth decades, although it can affect any age, and has a slight male preponder-
ance [3]. The classical presentation of the disease is with nephrotic syndrome, that 
is, the tetrad of leg swelling, proteinuria and serum hypoalbuminemia, with or 
without hypercholesterolemia. A number of patients have also been known to pres-
ent with venous thrombosis. This can be in the form of deep vein thrombosis (DVT) 
and, not uncommonly as the first presentation of the disease, with acute kidney 
injury (AKI) as a result of renal vein thrombosis. Hypercoagulopathy as a result 
of the loss of anti-thrombotic factors such as anti-thrombin III and plasminogen 
due to proteinuria, an increased level of factor VIII and fibrinogen, along with an 
increased platelet hyperaggregability has been noted in nephrotic syndrome what-
ever the cause. However, compared to other conditions that have a similar degree of 
proteinuria, MN has a relatively higher risk of venous thrombosis and its associated 
risks; the mechanism for this association has not been ascertained [4–6].
Clinically there are two distinct forms of MN, but these can be histologically 
very similar and difficult to differentiate. Both require very different treatment 
strategies and therefore distinguishing them is imperative. Primary MN accounts 
for the majority of patients (approximately 75–80%) and has now been shown to be 
an autoimmune disease. Secondary MN is caused by a multitude of causes including 
medications, systemic disorders and toxins, and its treatment is therefore aimed at 
the underlying trigger or condition [7].
It is one of the idiosyncrasies of MN that up to a third of patients if left 
untreated will achieve spontaneous remission within the first 2 years following 
diagnosis, and this potential for spontaneous remission has informed the current 
treatment options, especially for those patients without rapidly progressive renal 
decline [8]. The mainstay of treatment at present has a focus on the reduction of 
proteinuria with the use of an renin-angiotensin pathway blockade or immunosup-
pression if this fails [7]. It has also meant that for many studies, patients undergo 
three to 6 months of supportive care before they are eligible, in case any response to 
treatment seen is actually as a result of spontaneous remission. However, with the 
increasing use, understanding and monitoring of biomarkers such as anti-PLA2R, 
treatments are likely to be less empiric in the future.
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If patients do reach ESRD and receive a renal transplant, it has been well demon-
strated that this can provide a dramatic improvement to not only life expectancy but also 
quality of life [9–11]. However, this comes with the risk of recurrence of MN following 
transplantation (up to 34% of patients) despite the judicial use of immunosuppression 
and can lead to the loss of the graft in up to 50% of these cases. There is some evidence 
to suggest that receiving a transplant from a living related donor increases the risk of 
recurrence, but this is far outweighed by the complications associated with remaining on 
dialysis [12]. Current practice therefore, is to attempt to match HLA antigens as closely as 
possible to reduce the reliance on immunosuppression to minimise rejection.
For many patients, MN remains a relapsing and remitting disease, requiring 
lifelong follow up under the care of specialists in tertiary care. Despite being a 
rare condition, its chronicity, current standard treatments and their associated 
side-effects, the risk of ESRD, and disease recurrence means it is a disease that has 
a significant impact on both a patient’s quality of life and a healthcare system with 
finite resources.
3. Diagnosis
Recent advances in biomarker research for MN have shown promising results but 
at present diagnosis requires biopsy confirmation. Histologically the disease is charac-
terised by thickening of the glomerular basement membrane and spikes seen on silver 
stain. Immunofluorescence almost universally shows coarse granular immunoglobu-
lin IgG and complement C3 deposition on the capillary wall. Electron microscopy 
(EM) will show sub-epithelial immune complex deposition (Figure 1). It has become 
apparent over the years that the dominant IgG subclass found histologically (and 
for antibodies to PLA2R as described below) in primary MN is IgG4 [13–15]. This 
appears to differ from secondary MN where IgG1 predominates [16]. IgG makes up 
a significant proportion of serum protein in humans contributing approximately 
10–20% of circulating proteins. It can be further subdivided into four subclasses with 
differing effects. IgG4 is the least abundant of these subclasses and is generally found 
in response to allergens or in response to repeated exposure to an antigen [17].
New research findings suggest that there may be a class switch involved in 
primary membranous nephropathy. Here it has been shown that in early MN (stage 
I of the Ehrenreich and Churg scale) the predominant subclass of antibody is IgG1 
but as the disease progresses this changes so that IgG4 predominates [16].
4. Treatment
In primary MN, disease activity is still measured by proteinuria level and renal 
excretory function despite the advances in anti-PLA2R research. Proteinuria level 
has been shown to be not only a marker for remission when it is low but also predicts 
progression to ESRD when increased. If proteinuria reduces through either sponta-
neous remission or with treatment, then the risk of CKD progression also falls. It is 
for this reason that the main focus of treatment in primary MN is concerned with 
control of proteinuria, with or without the use of immunosuppression, generally in 
the form of the Ponticelli regime (or calcineurin inhibitors if cyclophosphamide is 
not tolerated or is contraindicated). This regime of rotating high dose intravenous 
steroids and immunosuppression was first described in the mid-1980s and has 
been the recommended regime since [7, 18–20]. Despite its success in treating the 
condition, the Ponticelli regime comes with a significant side effect burden, includ-
ing an increased risk of infection, osteoporosis, diabetes mellitus, weight gain, 
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haemorrhagic cystitis, infertility and malignancy [18]. It is this that has led many 
researchers to search for an alternative therapy including mycophenolate mofetil and 
tacrolimus but with variable evidence to show an improvement in outcomes.
Rituximab is a monoclonal antibody against CD20, found on the B-cells, which 
leads to a reduction in B-cell numbers and has been used extensively in cancer therapy 
and autoimmune diseases since its introduction in the 1990s. A number of case series 
and studies have shown the potential that Rituximab can have for primary MN, but 
so far there has only been one randomised controlled trial (RCT) [21–24]. Here it has 
been shown that compared to standard anti-proteinuric therapy, patients treated with 
rituximab show a greater reduction in anti-PLA2R levels at month 3, followed by a 
later reduction in proteinuria, increase in serum albumin and are more likely to enter 
remission [24]. Combined with the high cost of the medication itself, its widespread 
use has been restricted in resource-limited, evidence-based healthcare systems, such 
as the NHS in UK [25]. The use of Rituximab therapy is currently under investiga-
tion in the MENTOR study in North America and via the Commissioning through 
Evaluation pathway run under the auspices of the National Institute for Health and 
Care Excellence (NICE) in the UK. It is possible that based on these two studies the 
use of Rituximab will become more ubiquitous in the near future.
5. Future novel treatments
The use of many of these medications comes with side effects that can be unpal-
atable to the patient and physician and the search for treatments with a reduced 
Figure 1. 
Histological appearance of membranous nephropathy (a) haematoxylin and eosin stain (H&E) showing 
marked capillary loop thickening (b) silver staining showing spikes (c) electron microscopy of MN showing 
sub-epithelial immune complex deposition (d) immunofluorescence showing IgG deposition on the capillary 
wall. Figures courtesy of Dr. Lorna Williams, Consultant Histopathologist, Manchester University Hospitals 
Foundation Trust, UK.
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side-effect profile is on-going. Treatments such as immunoadsorption (IA) allow 
for the controlled removal of antibodies without the side effects associated with 
immunosuppression. Immunoadsorption RCTs in MN though, are non-existent and 
certainly not in the anti-PLA2R era. Immunoadsorption is a method of removing 
specific circulating immunoglobulins from the blood and has been shown to remove 
over 80% of circulating IgG with a single session adsorption of 2.5 plasma volumes, 
with albumin and antithrombin III almost unaffected [26]. With multiple sessions, 
this can rise to over 98% [27]. These are removed in the absorber through binding 
Peptide-GAM. Using two columns per machine, one regenerating whilst the other 
is removing antibodies; the process can occur indefinitely until the required level of 
antibody has been removed.
Post IA it appears that autoantibodies can be slow to re-emerge. Use in dilated 
cardiomyopathy for the removal of β1-adreno-receptor autoantibodies (β1-AAB) 
has shown that only a small minority of patients (0% in the first year and 15% by 
3 years) will show an increase in significant β1-AAB autoantibodies [28, 29].
To our knowledge, there has only been one publication using immunoadsorp-
tion for the treatment of MN [30]. In 1999, Esnault et al. successfully used IA for 
the treatment of various aetiologies of Nephrotic syndrome including four patients 
with MN [31]. Here they showed that not only is the procedure safe but that there 
was a significant improvement in proteinuria in all patients with membranous 
nephropathy. The main side effect in this group of patients was headache, which 
resolved without sequelae. Since that time the treatment has been used in numer-
ous other autoimmune conditions including Focal Segmental Glomerulosclerosis 
(FSGS) [32], systemic lupus nephritis (SLE) [33, 34], ANCA-associated small vessel 
vasculitides [35, 36], Anti-glomerular basement membrane antibody disease [37] 
and in renal transplantation [38–40].
In conditions such as SLE, the use of immunoadsorption can dramatically reduce 
the level of circulating immune complexes and autoantibodies leading to clinical 
improvement in even severe life-threatening SLE. These results have been shown 
with as little as two sessions within 3 days and repeated every 3 weeks if patients 
remain with active disease [33]. With the current understanding of primary MN’s 
autoimmune process, the use of IA could provide the ability to rapidly remove the 
pathogenic antibodies leading to remission. Current IA machines can remove the 
different classes such as IgG4 with an increased specificity but cannot differentiate 
further than that. If IA is proved to work for primary MN, it may be possible to 
develop an IA column that is specific only for anti-PLA2R, therefore allowing for an 
even more targeted and personalised treatment.
6. Autoimmune membranous nephropathy
Until recently autoimmune (or primary) MN was known as idiopathic MN as its 
cause remained unclear. It was generally a diagnosis of exclusion, once a patient had 
biopsy confirmation of MN and all causes of secondary MN had been ruled out. It 
was for a long time postulated to be an autoimmune disease, but the target antigen 
in humans remained elusive. In the late 1970s, work on the Heymann Nephritis rat 
model of experimental MN showed that circulating IgG antibodies could bind to 
the podocytes [41–43]. The target antigen was found to be megalin, but this was not 
present on human podocytes, so the search for the target antigen continued. It was 
not until 2009, almost 40 years later that this was discovered. Here Beck et al. used 
western blotting with MN patient sera, to show that antibodies bound to a 185 kDa 
protein band from glomerular extracts. This band was only seen in the primary MN 
group and not seen in normal patients or other proteinuric conditions including 
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patients with secondary MN. Using mass spectrometry this band was found to 
contain the M-type phospholipase A2 receptor 1 (PLA2R) [15]. Since then, the 
increased interest and research into MN has led to the discovery of a second minor 
target antigen in thrombospondin type-1 domain containing 7A (THSD7A) [44].
7. M-type phospholipase A2 receptor 1
The landmark paper by Beck et al. describing the discovery of autoantibodies 
to PLA2R found on human podocytes transformed our understanding of the MN 
disease process. Here was evidence that for the majority of patients with MN, the 
condition was, as had been postulated, an autoimmune disease [15].
PLA2R is a transmembrane receptor for Phospholipase A2, a protein from the 
mannose receptor family, one of four described in humans; Endo180, DEC205, 
Mannose Receptor (MR) and PLA2R [45–47]. As with all the mannose receptor 
family, the transmembrane glycoprotein has an extracellular component, in the case 
of PLA2R, this is made up of an N-terminal ricin rich domain, a fibronectin type II 
domain and 8 C-type lectin domains (CTLDs) [48]. In the kidney, it is found almost 
exclusively on the podocytes, but it has also been found on neutrophils and in the 
lung [49, 50]. Its function in the kidney remains unknown, however, and how the 
anti-PLA2R antibodies alter its normal function leading to proteinuria, if indeed 
that is what is part of the process, also remains unknown [15, 51].
The predominant antibody to PLA2R is IgG and in particular IgG4, which is 
the major component of immune complex deposition in primary MN [13, 14]. 
These immune complexes appear to form in the kidney with the IgG4 antibodies 
and the PLA2R antigen being co-localised, giving further evidence for the role 
of PLA2R in the disease process [52, 53]. The fact that the complexes form in situ 
in the kidney may explain why some patients with biopsy-proven MN and clini-
cal evidence for the disease are serum anti-PLA2R negative. Debiec and Ronco 
showed in 2011 that there were a number of patients who were serum anti-PLA2R 
negative but had detectable PLA2R in glomerular deposits. They did also find a 
few patients with no PLA2R in the glomerular deposits but who were serologi-
cally positive [54]. We know that anti-PLA2R antibodies have a high affinity for 
PLA2R in the podocytes and it may be that a certain level of deposition is required 
to overload the system before the anti-PLA2R antibodies become serologically 
detectable [48].
Much of the excitement surrounding anti-PLA2R is due to its apparent patho-
genicity with the resultant potential for use as a biomarker and as a treatment 
target. Several studies have provided evidence for its pathogenicity showing that a 
high titre correlates with disease activity. For patients who go into remission either 
spontaneously or through the use of immunosuppression, the anti-PLA2R level falls 
months before this becomes clinically apparent with a fall in proteinuria. If a patient 
relapses, this again is predated by a rise in antibody titres [55–60].
Outcomes can also be predicted with high titres predicting a worse outcome in 
regards to renal function and an improved outcome with low titres [55]. If treat-
ment does not result in antibody negativity, then they are left with a high risk of 
relapse [51, 57]. Ruggenenti et al. have shown similar results with a reduction in 
anti-PLA2R levels strongly predicting remission and increasing titres following this, 
predicting relapse [59].
With the increasingly strong evidence for the involvement of anti-PLA2R 
antibodies in the pathogenesis of primary MN, the focus has now shifted to trying 
to understand the antigen and its interaction with the autoantibody. Work carried 
out in Manchester has now determined the major epitope on the PLA2R antigen 
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that is recognised by the anti-PLA2R antibodies. Four different sized fragments 
of extracellular PLA2R (full-length N-C8, N-terminus to C-type lectin domain 
(CTLD) 3 (N-C3), N-terminus to CTLD2 (N-C2) and a ricin rich domain) were 
used to investigate the reactivity of human anti-PLA2R autoantibodies. It was 
found that the major epitope was located in the N-C3 region of the receptor. The 
antibodies were also found to bind with an equal affinity to the four different 
fragments, confirming the existence of a single epitope. The epitope itself is a 
31-mer peptide made up of the beta-1 and beta-3 strands and encompassing the 
beta-2 strand [48].
Leading on from this the Manchester team also constructed a 3D model of the 
structure of the immune complex incorporating the extracellular N-C8 PLA2R and 
the autoantibody with the binding site [48]. This work has been further confirmed 
by Kao et al. who found that the dominant epitope is in the N-terminal region as 
well, in particular in the region from the ricin rich domain through the fibronectin-
like type to the CTLD1 [61].
8. Thrombospondin type-1 domain-containing 7A
The fact that anti-PLA2R antibodies are found in up to 80% of patients with 
primary MN raises a number of possibilities. It is known that some patients with 
secondary membranous can develop malignancies years after the diagnosis of MN 
and it may be that these patients fall into this category. Whether these patients 
represent a cohort who have two separate conditions and it is coincidental that one 
is known to cause the other is still up for debate. A second possibility is that there 
are more pathogenic antigens leading to the formation of autoantibodies than previ-
ously thought. In fact, for a small number of patients with primary MN, this seems 
to be the case.
Using western blotting, Thomas et al. discovered a glomerular protein of 
250 kDa in patients with anti-PLA2R negative biopsy-proven membranous 
nephropathy. This corresponded to THSD7A, a protein found in the podocyte foot 
processes [44].
They went on to show that the predominant antibody to this antigen was 
IgG4 in keeping with a diagnosis of primary MN, and on histological staining, in 
a similar fashion to anti-PLA2R, the immune complexes were co-localised with 
the antigen. Levels of the antibody were shown to correlate with disease activ-
ity, being higher in active disease and lower as the clinical manifestations of the 
disease improved. Interestingly, there appeared to be no statistical significance in 
the clinical presentation or demographics between the anti-PLA2R positive and 
the anti-THSD7A positive patients, except for a slightly higher number of women 
in the anti-THSD7A group, although this is believed to be due to the small num-
bers involved.
This evidence suggests that for a minority of primary MN patients, approxi-
mately 2.5–5% in this study, a second unrelated and discrete antigen is involved 
with the pathogenesis of the disease [44]. Whether this all represents a separate 
disease and whether there are other minor antigens still to be discovered remains 
unknown as does the major epitope in THSD7A. However, for PLA2R, in addition to 
the major epitope in the CysR domain, evidence from the work of Fresquet et al. on 
the identification of the major epitope of PLA2R, showed that 10% of anti-PLA2R 
positive sera reacted with an epitope at CTLD4-8. This suggests that there may be 
a further, as yet unidentified, antibody to this minor epitope [48]. This idea of epi-
tope spreading has been suggested by Lambeau et al. who have defined additional 
epitopes in CTLD1 and CTLD7 domains [62].
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9. The multi-hit hypothesis
9.1 Genetic association
Why some patients develop an autoantibody to PLA2R is still an unknown, but 
it does appear to have a strong genetic component. The first clue to the genetic basis 
of the disease was the discovery of the association with Human Leucocyte Antigen 
(HLA)—DR3 followed closely by the identification of familial clustering in 1984 
[30, 63, 64]. Following the discovery of the PLA2R antigen, researchers studying 
Korean and Chinese populations investigated the association of a number of single 
nucleotide polymorphisms (SNPs) known to be associated with PLA2R. They both 
found that a polymorphism at rs35771982 was significantly associated with primary 
MN. Interestingly, this polymorphism is located on CTLD1, in the region that was 
later found to contain an epitope in the antigen [48, 65, 66].
The major Genome-Wide Association Study (GWAS) in MN of 556 patients 
(French, Dutch and British) revealed two major loci of allelic association. The first 
is not unexpectedly on chromosome 6p21 within HLA-DQA1 gene, and the second 
is on chromosome 2q24 containing PLA2R1. For patients who were homozygous 
for these alleles, their odds ratio for having primary membranous nephropathy was 
78.5 [67]. This work has recently been validated in a study using genotype and HLA 
imputation alongside a GWAS in 323 patients with primary MN. Here the associa-
tion of HLA-DQA1 and PLA2R1 with primary MN was confirmed, without detect-
ing any other novel signals [68].
How these genetic markers modulate the risk of developing MN is unknown. 
The idea that the genetically restricted class II presentation of PLA2R peptides to 
affect the class switch to high-affinity IgG anti-PLA2R is a theory that remains to  
be tested.
9.2 Environmental trigger
Indicative of the rapid pace of research into primary MN since the discovery of 
the PLA2R antigen, we now have not only the clinical correlation of the antibody 
with disease activity but also the major epitope on the antigen and evidence for 
the genetic polymorphism located in the antigen itself. This, however, does not 
completely explain the development of the disease. The polymorphisms described 
in these studies are actually variants that are common to the general population. It 
seems likely that, similar to other autoimmune diseases such as IgA nephropathy, 
primary MN is a multi-hit disease. A patient with the polymorphism has a genetic 
predisposition but to develop the disease needs an external trigger.
Fresquet et al. have shown that an amino acid sequence which is part of the 
dominant epitope in the CysR region of the PLA2R antigen is also found in the 
cell wall of some species of clostridia [48]. Further searches using the Basic Local 
Alignment Search Tool (BLAST) [69] has shown this peptide sequence is found 
in a number of other common pathogens such as Pseudomonas and Saccharomyces 
cerevisiae.
There is now also emerging evidence implicating air pollution in the develop-
ment of autoimmune MN. A recent large study in China investigating the emerg-
ing trends of glomerulopathy based on renal biopsies in relation to air pollution 
noted a rise in the incidence of MN in all age ranges and in all regions, this is in 
contrast to other glomerular disease investigated which all remained the same. 
It was more prevalent in areas with the highest air pollution and the long-term 
average was found to be associated with a significantly increased risk of autoim-
mune MN.
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9.3 Loss of tolerance
What is not known at present is the risk of developing autoimmune MN if you 
have the genetic predisposition, only that you are more likely to have the risk alleles 
if you have autoimmune MN. What remains elusive is how a patient’s immune 
system converts from an advantageous defence against common pathogens to a 
pathogenic entity in itself. A characteristic of autoimmune MN is the heterogene-
ity shown in prognosis and its waxing and waning nature over time. A proportion 
of patients will undergo a phenomenon of spontaneous remission, and in patients 
with a more severe phenotype, it is not unusual for them to follow a relapsing and 
remitting course. Many patients, when they first come to medical attention, will 
describe self-limiting episodes many months or years prior to their diagnosis that is 
likely to be nephrotic states and the first signs of the disease. This suggests that far 
from being a continuously progressive immunological process, particularly in light 
of the pathogenicity of the autoantibody, that there may be natural mechanisms at 
play attempting to maintain a balance. Work in other autoimmune diseases such as 
autoimmune thyroiditis has proven the existence of antigens capable of maintaining 
a population of natural T Regs and thereby keeping pathogenic antibodies sup-
pressed [70].
As the technology evolves, flow cytometry is becoming an ever more powerful 
tool for the study of the immune system. A recent study using patients enrolled 
in the GEMRITUX trial showed that patients had lower proportions of IgD− and 
IgD+ memory B cells, T Regs and a higher proportion of naïve B cells at baseline 
compared to healthy donors [71]. In this study by Rosenzwajg et al., patients who 
responded to treatment were observed to have a lower proportion of T Regs at 
baseline compared to those who did not respond to treatment. They also noted that 
in patients with no response to treatment, there was no increase in T Regs following 
treatment, however in patients who went on to respond, there was a significantly 
higher proportion of T Regs at day 8 compared to baseline [71].
This is similar to work currently being undertaken in our lab (unpublished) in 
which flow cytometry was used to model the immune system following treatment 
with immunoadsorption [72]. In our cohort, we also found that there was a lower 
proportion of IgD+ memory B cells in the patient group but a similar level of IgD− 
memory B cells albeit with a much larger range. For the Naïve B cells and T Regs, 
the medians were very similar between the patients and control group but with a 
much larger range in the patient cohort. One of the striking differences between our 
patient group and the control group at baseline is that there does not seem to be any 
statistical difference in PLA2R positive B cells, with a number of volunteers in the 
control group showing a relatively high proportion of these cells. This seemingly 
counterintuitive result, in fact, appears to add weight to the importance of loss of 
tolerance in the disease process.
Given the shared sequence of amino acids (SVLTLENC), it could be expected 
during the development of normal natural immunity to a range of pathogens, 
developing IgM antibodies to this linear peptide sequence is common, entirely 
normal and beneficial to the host. The risk of developing an autoimmune pathol-
ogy only arises then, if a patient has the genetic makeup (pathological alleles of 
DQA1 and PLA2R) required to present PLA2R T cell peptides to their immune 
system. Only with the permissive genetic background and continued exposure to 
the pathogen or environmental trigger, causing immune processing of PLA2R, will 
class switching occur from IgM to IgG, and therefore allowing the development of 
pathogenic high-affinity antibodies. In our PLA2R panel, the healthy control group 
showed a significant level of PLA2R positive B cells. A current on-going and unpub-
lished project being carried out in our lab is the development of an IgM anti-PLA2R 
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ELISA. Although it cannot be proven in the current flow cytometry experiment, 
it would appear to suggest that there is a high likelihood that the B cells seen in the 
healthy population may, in fact, be IgM positive B cells as opposed to being IgG 
positive.
A further interesting dimension to immune regulation and loss of tolerance 
that needs further study is the role that T reg cells play and how they are a poten-
tial mechanism for the suppression of pathogenic antibodies. The relapsing and 
remitting nature of autoimmune membranous nephropathy and the phenomenon 
of spontaneous remission indicates that at some level there must be an immune 
mechanism capable of suppressing the anti-PLA2R antibodies, much like that found 
in autoimmune thyroiditis. Another on-going study, again unpublished, in our lab 
has identified a number of healthy controls without the prerequisite HLA-DQA1 or 
PLA2R1 genes needed to develop autoimmune MN, who have a detectable level of 
circulating soluble PLA2R using mouse anti-PLA2R as the capture antibody. There is 
the potential that these circulating soluble-PLA2R antigens are active in maintain-
ing a functioning level of T Regs to suppress class switching and downregulate the 
pathogenic antibody level. If natural T Regs did indeed have a role in keeping the 
pathogenic IgG anti-PLA2R antibodies suppressed, the expectation would be that in 
times of active disease the levels would be low. The opposite would also be true with 
high levels in times of remission or just before remission or response to treatment. 
The T cell panel used for the patient cohort does start to show a pattern of T Regs 
change over time, a pattern that appears to support the theory above, especially 
when taken in the context of antibody level. At week 4 follow up, the T Regs level 
has dropped to their lowest point, this is also at the same time point at which the 
anti-PLA2R is at its highest. The proportion of T Regs then show an increase at both 
week 10 and week 16 follow up, just as the antibody level is decreasing.
10. Summary
Autoimmune MN has experienced a step change in our understanding of the 
disease pathogenesis since the discovery of the anti-PLA2R autoantibody in 2009 
[15], however, there is much that still remains unknown. Despite the advances seen 
over the last decade, the management of the disease remains an empirical treat-
ment based on a regimen first introduced over two decades ago. There is as yet no 
disease-specific therapy or alternative to glucocorticoids and immunosuppression 
in mainstream use.
As with all autoimmune diseases, the eventual clinically apparent symptoms are 
the end result in a journey of multiple steps, the so-called multi-hit hypothesis. We 
know that there is a strong genetic component in the development of the disease, 
with patients homozygous for both the HLA-DQA1 and PLA2R1 genes are almost 
80 times more likely to develop the disease than patients who do not [67]. What we 
still do not know is whether the possession of these genes in itself guarantees the 
development of the disease. It is likely that a further trigger (likely environmental) 
is required to progress to the disease state.
Development of the normal natural immunity requires the production of 
antibodies, including IgM, to linear peptides in a whole range of epitopes. With this 
beneficial protective immunity, circulating IgM antibodies to the PLA2R p28mer 
peptide can, in fact, be a normal occurrence. The presence of these antibodies in 
patients without the genetic predisposition to the disease would just be an expected 
variant of normal. It is in those patients who do have the genetic predisposition to 
developing the disease, that the presence of IgM antibodies with the ability to rec-
ognise the p28mer will have the potential to progress to the disease state to generate 
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a high-affinity IgG response. Once this occurs, and there is recognition of the 
podocyte PLA2R epitope there begins a positive reinforcement with ever-increasing 
affinity. The exact nature of how patients eventually develop a pathogenic IgG 
antibody remains elusive. However, there is now tentative emerging evidence show-
ing that in a control group of healthy volunteers and a patient group with active 
disease there is a PLA2R antigen positive B cell population in both. This is coupled 
with an on-going unpublished study showing a level of circulating anti-PLA2R IgM 
antibodies in these normal healthy patients. This requires further work, but it is the 
first evidence for an antibody class switch in autoimmune MN.
There is also data showing that as the anti-PLA2R antibody rises in the weeks 
following treatment, there is a reduction in the natural T Regs. Following this, as the 
level of T Regs starts to rise there is a corresponding fall in the antibody level. Taken 
in tandem with unpublished work that is on-going showing a measurable level of 
circulating soluble PLA2R in healthy controls, this would appear to show that a 
similar process to autoimmune thyroiditis is taking place in autoimmune MN.
There do remain a number of important questions in relation to the disease 
pathogenesis though; how does the anti-PLA2R attaching to the epitope causes the 
damage we see? Despite strong circumstantial evidence suggesting its pathogenic-
ity, direct evidence is currently lacking. Can the antibody titre supplant the need for 
a renal biopsy? How many patients who have the genetic predisposition eventually 
go on to develop the disease and is there a way to predict which patient does? And 
are there more autoantibodies associated with the development of autoimmune 
membranous nephropathy.
Current understanding of the role anti-PLA2R plays in the pathogenesis has 
now led many to envisage a greater role for its use in clinical practice. Not only is it 
increasingly being used for disease monitoring and for prognosticating treatment 
response but it is also becoming a necessary tool for diagnosis. This has the distinct 
prospect of drastically altering the current diagnostic pathway and ultimately a 
patients quality of life. A number of groups are now actively investigating the feasi-
bility of serum anti-PLA2R negating the need for a renal biopsy, not only reducing 
time to diagnosis but also avoiding the need for an invasive procedure.
The hope is that by understanding the pathway of disease in this and other 
autoimmune conditions, new safer and more efficacious treatment options will be 
available for patients in the future. This is particularly pertinent given the increas-
ing incidence of autoimmune diseases worldwide and the increased burden on 
patients and healthcare systems.
Glomerulonephritis and Nephrotic Syndrome
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